Brief: BD, Labcorp Collaborate To Develop Flow Cytometry-Based Companion Diagnostics For Matching Patients With Treatments
Aug 9 (Reuters) - Becton Dickinson and Co BDX.N :
* BD, LABCORP COLLABORATE TO DEVELOP FLOW CYTOMETRY-BASED
COMPANION DIAGNOSTICS FOR MATCHING PATIENTS WITH TREATMENTS
* BD - COLLABORATION WITH LABCORP TO DEVELOP, MANUFACTURE,
MARKET
AND COMMERCIALIZE FLOW CYTOMETRY-BASED COMPANION DIAGNOSTICS
(CDX)
* BD - AGREEMENT CREATES FRAMEWORK FOR COMPANIES TO
COLLABORATE ON
FLOW CYTOMETRY-BASED CDX OPPORTUNITIES WITH PHARMACEUTICAL
PARTNERS
Source text for Eikon: ID:nPnbY9tTXa
Further company coverage: BDX.N
Recent news on Laboratory of America Holdings
See all newsBrief: Labcorp To Announce Second Quarter 2026 Financial Results On July 30, 2026
Brief: Labcorp And Epic Expand Collaboration To Advance Diagnostic Integration Across Hospitals And Health Systems
U.S. STOCKS ON THE MOVE-Quanta, O'Reilly Automotive, Avis
Labcorp lifts full‑year forecast as diagnostics business stays resilient (updated)
U.S. STOCKS ON THE MOVE-Qualcomm, Meta, Cardinal Health